Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Gross Profit
Sonoma Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Gross Profit
$4.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$57.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$40.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$44.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$27B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
See Also
What is Sonoma Pharmaceuticals Inc's Gross Profit?
Gross Profit
4.8m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Gross Profit amounts to 4.8m USD.
What is Sonoma Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
-6%
Over the last year, the Gross Profit growth was 23%. The average annual Gross Profit growth rates for Sonoma Pharmaceuticals Inc have been -18% over the past three years , -10% over the past five years , and -6% over the past ten years .